Gross-to-Net Simplified:
A Clear Path from Any
Stage to Mastery
Understanding GTN Maturity and How to
Progress Step by Step in Life Sciences
Access the Full White Paper
Get actionable insights you can apply immediately to drive better results..
Executive Summary
Gross-to-Net (GTN) management has become one of the most misunderstood yet mission-critical disciplines in life sciences. Across pharmaceuticals, biotech, and medical devices, companies face increasing complexity in rebates, chargebacks, returns, and government pricing compliance. Yet, many organizations still rely on fragmented systems and manual processes—limiting visibility and control. This white paper helps leaders assess where they stand on the GTN maturity curve and outlines a clear, practical path to move from any level to mastery. Whether you’re just starting your GTN journey or seeking to optimize a mature operation, this guide provides a simple framework for progress—grounded in Results, Simplicity, Flexibility, and Trust.
Gross-to-Net represents the true revenue a company retains after all deductions—rebates, chargebacks, returns, and allowances. In practice, GTN touches nearly every function: Finance, Market Access, Contracting, and Commercial. As portfolios expand and payer models evolve, GTN complexity increases exponentially. Common challenges include:
Many companies treat GTN as an accounting task rather than a strategic capability. This white paper reframes GTN as a driver of governance, margin control, and operational confidence—and shows how to simplify it, step by step.